Pharmaceutical Benefits Scheme – new and amended listings – Hepatitis C medicines

There have been 5 new medicines added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of Hepatitis C, providing more affordable access to vital medicines.

Information update: this Budget measure is not subject to the passage of legislation.

Description of measure

There have been 5 new medicines added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of Hepatitis C, providing more affordable access to vital medicines.

The new medicines have a dual listing on the PBS under both Section 85, for community access, and Section 100, which includes prisoner access. This will ensure all eligible people have access to the medications regardless of the clinical setting. 

From 1 March 2016, the following medicines were listed:

  • sofosbuvir
  • ledipasvir with sofosbuvir
  • daclatasvir

From 1 May 2016, the following medicines were listed:

  • paritaprevir with ritonavir, ombitasvir and dasabuvir
  • paritaprevir with ritonavir, ombitasvir, dasabuvir and ribavirin

The Hepatitis C suite of medicines can be prescribed by a:

  • gastroenterologist
  • hepatologist
  • infectious disease physician experienced in the treatment of Hepatitis C infection, or
  • general practitioner in consultation with a specialist

Questions and answers

Who is eligible for this measure

Eligible Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements will be able to access these medicines under the PBS if prescribed by their health professional.

Patients pay part of the cost of a PBS medicine to the pharmacy at the time of supply. The maximum patient contribution rates are adjusted on 1 January each year in line with inflation.

The date this measure will start and finish

This measure started on 1 March 2016 and is ongoing.

Page last updated: 12 September 2016

This information was printed Monday 26 September 2016 from humanservices.gov.au/corporate/budget/budget-2016-17/health-matters-and-health-professionals/pharmaceutical-benefits-scheme-new-and-amended-listings-hepatitis-c-medicines It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.